RU2008133287A - PHARMACEUTICAL GEL-CONTAINING COMPOSITION FOR LOCAL AND OUTDOOR USE - Google Patents
PHARMACEUTICAL GEL-CONTAINING COMPOSITION FOR LOCAL AND OUTDOOR USE Download PDFInfo
- Publication number
- RU2008133287A RU2008133287A RU2008133287/15A RU2008133287A RU2008133287A RU 2008133287 A RU2008133287 A RU 2008133287A RU 2008133287/15 A RU2008133287/15 A RU 2008133287/15A RU 2008133287 A RU2008133287 A RU 2008133287A RU 2008133287 A RU2008133287 A RU 2008133287A
- Authority
- RU
- Russia
- Prior art keywords
- metronidazole
- active substance
- following ratio
- mixture
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 14
- 239000013543 active substance Substances 0.000 claims abstract 13
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract 13
- 229960000282 metronidazole Drugs 0.000 claims abstract 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 9
- 229960004236 pefloxacin Drugs 0.000 claims abstract 8
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims abstract 8
- 229960004393 lidocaine hydrochloride Drugs 0.000 claims abstract 7
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 claims abstract 7
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims abstract 4
- 229960003260 chlorhexidine Drugs 0.000 claims abstract 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 4
- PWSZSZJBVQXJIX-IKHZIZRMSA-N (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol 2-methylnaphthalene-1,4-dione (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound CC1=CC(=O)c2ccccc2C1=O.C\C(=C/CO)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C.CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCc2c(C)c(O)c(C)c(C)c2O1 PWSZSZJBVQXJIX-IKHZIZRMSA-N 0.000 claims abstract 3
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims abstract 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims abstract 3
- 229960003957 dexamethasone Drugs 0.000 claims abstract 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract 3
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims abstract 3
- 229960005287 lincomycin Drugs 0.000 claims abstract 3
- 210000002200 mouth mucosa Anatomy 0.000 claims abstract 3
- 208000035473 Communicable disease Diseases 0.000 claims abstract 2
- 206010052428 Wound Diseases 0.000 claims abstract 2
- 208000027418 Wounds and injury Diseases 0.000 claims abstract 2
- PYFOCTCWWQCCGP-UHFFFAOYSA-J [Ti+4].OCC(O)C([O-])=O.OCC(O)C([O-])=O.OCC(O)C([O-])=O.OCC(O)C([O-])=O Chemical class [Ti+4].OCC(O)C([O-])=O.OCC(O)C([O-])=O.OCC(O)C([O-])=O.OCC(O)C([O-])=O PYFOCTCWWQCCGP-UHFFFAOYSA-J 0.000 claims abstract 2
- 229960003405 ciprofloxacin Drugs 0.000 claims abstract 2
- 229940087211 ciprofloxacin and metronidazole Drugs 0.000 claims abstract 2
- 230000002458 infectious effect Effects 0.000 claims abstract 2
- 239000008252 pharmaceutical gel Substances 0.000 claims abstract 2
- 229910052710 silicon Inorganic materials 0.000 claims abstract 2
- 239000010703 silicon Substances 0.000 claims abstract 2
- 210000004872 soft tissue Anatomy 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 239000010936 titanium Substances 0.000 claims abstract 2
- 229960001193 diclofenac sodium Drugs 0.000 claims 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1. Фармацевтическая гелесодержащая композиция для местного и наружного применения, содержащая активное вещество и носитель, отличающаяся тем, что в качестве носителя она содержит глицерогидрогель на основе сольватокомплексов глицератов кремния и титана состава 2Si(С3Н7O3)4·Тi(С3Н7O3)4·хС3Н8О3·уН2O, где 9≤x≤30, 60≤у≤120 при следующем соотношении компонентов, мас.%: ! активное вещество0,5-7,0носительостальное ! 2. Фармацевтическая композиция по п.1, отличающаяся тем, что в качестве активного вещества используют смесь ципрофлоксацина и метронидазола и, необязательно, лидокаина гидрохлорид, для лечения гнойно-воспалительных заболеваний кожи и мягких тканей при следующем соотношении компонентов, мас.%: ! ципрофлоксацин0,25-1,0метронидазол0,25-1,0лидокаина гидрохлорид0,0-1,0 ! 3. Фармацевтическая композиция по п.1, отличающаяся тем, что в качестве активного вещества используют смесь пефлоксацина и метронидазола и аекола для лечения ожогов и "чистых" ран при следующем соотношении компонентов, мас.%: ! пефлоксацин0,25-1,0метронидазол0,25-1,0аекол3,0-5,0 ! 4. Фармацевтическая композиция по п.1, отличающаяся тем, что в качестве активного вещества используют смесь пефлоксацина и метронидазола и хлоргексидина биглюконат для лечения инфекционно-воспалительных заболеваний слизистой оболочки полости рта при следующем соотношении компонентов, мас.%: ! пефлоксацин0,25-1,0метронидазол0,25-1,0хлоргексидина биглюконат (в форме 20% раствора)0,05-0,25 ! 5. Фармацевтическая композиция по п.1, отличающаяся тем, что в качестве активного вещества используют смесь линкомицина и метронидазола и дексаметазона и, необязательно, лидокаина гидрохлорид для лечения воспалительных заб�1. Pharmaceutical gel-containing composition for local and external use, containing the active substance and a carrier, characterized in that it contains a glycerohydrogel based on solvate complexes of silicon and titanium glycerates of the composition 2Si (C3H7O3) 4 · Ti (C3H7O3) 4 · xC3H8O3 · yH2O where 9≤x≤30, 60≤y≤120 in the following ratio of components, wt.%:! active substance 0.5-7.0 2. The pharmaceutical composition according to claim 1, characterized in that a mixture of ciprofloxacin and metronidazole and, optionally, lidocaine hydrochloride, is used as the active substance for the treatment of purulent-inflammatory diseases of the skin and soft tissues in the following ratio of components, wt.%:! ciprofloxacin 0.25-1.0 metronidazole 0.25-1.0 lidocaine hydrochloride 0.0-1.0! 3. The pharmaceutical composition according to claim 1, characterized in that the active substance is a mixture of pefloxacin and metronidazole and Aekol for the treatment of burns and "clean" wounds in the following ratio, wt.%:! pefloxacin 0.25-1.0 metronidazole 0.25-1.0 acol 3.0-5.0! 4. The pharmaceutical composition according to claim 1, characterized in that a mixture of pefloxacin and metronidazole and chlorhexidine bigluconate is used as the active substance for the treatment of infectious and inflammatory diseases of the oral mucosa in the following ratio, wt.%:! pefloxacin 0.25-1.0 metronidazole 0.25-1.0 chlorhexidine bigluconate (in the form of a 20% solution) 0.05-0.25! 5. The pharmaceutical composition according to claim 1, characterized in that the active substance is a mixture of lincomycin and metronidazole and dexamethasone and, optionally, lidocaine hydrochloride for the treatment of inflammatory
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008133287/15A RU2417102C2 (en) | 2008-08-13 | 2008-08-13 | Gel-containing pharmaceutical composition for local and external application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2008133287/15A RU2417102C2 (en) | 2008-08-13 | 2008-08-13 | Gel-containing pharmaceutical composition for local and external application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008133287A true RU2008133287A (en) | 2010-02-20 |
| RU2417102C2 RU2417102C2 (en) | 2011-04-27 |
Family
ID=42126754
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008133287/15A RU2417102C2 (en) | 2008-08-13 | 2008-08-13 | Gel-containing pharmaceutical composition for local and external application |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2417102C2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040107A1 (en) * | 2015-09-04 | 2017-03-09 | Indiana University Research & Technology Corporation | Antibiotic gel formulation and methods of preparing the antibiotic gel formulation |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103142701A (en) * | 2013-03-29 | 2013-06-12 | 武汉中博绿亚生物科技有限公司 | Ear dropping oil agent for mixed infection of pet ear canal and preparation method thereof |
| RU2623153C2 (en) * | 2015-11-24 | 2017-06-22 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) | Silicon-zinc-boron-containing glycerogydrogel for local application, facilitating for vulnerary, regenerative, bactericidal and antifungal activity |
| RU2707278C1 (en) * | 2019-06-06 | 2019-11-26 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук | Agent for treating inflammatory diseases of the joints |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2042683C1 (en) * | 1993-06-23 | 1995-08-27 | Светлана Николаевна Киппер | Aqueous-glycerol complex (2,3-dihydroxypropyl)-ortho-titanate hydrochloride and pharmaceutical gel-containing composition on its basis |
-
2008
- 2008-08-13 RU RU2008133287/15A patent/RU2417102C2/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017040107A1 (en) * | 2015-09-04 | 2017-03-09 | Indiana University Research & Technology Corporation | Antibiotic gel formulation and methods of preparing the antibiotic gel formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2417102C2 (en) | 2011-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2218264T3 (en) | USE OF CHEMOTHERAPICS FOR TOPICAL TREATMENT. | |
| ATE369353T1 (en) | MEDICALLY USABLE ARYLETHANOLAMINE COMPOUNDS | |
| CN107536725A (en) | A kind of multiple-effect oral cavity composition and its application containing hyaluronic acid mixtures | |
| ATE381537T1 (en) | FORMANILIDE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | |
| CY1107850T1 (en) | THIADIAZYLOPIPERAZINE PRODUCT WITH USE IN APTROPIC OR IN ACTION AGAINST ALGUES | |
| MX340965B (en) | Combinations for the treatment of diseases involving cell proliferation. | |
| TW200500358A (en) | Compounds | |
| BG106825A (en) | Substituted oxazolidinones and their use in the field of blood coagulation | |
| CY1108992T1 (en) | USE OF HYALURONIC ACID FOR PREPARATION OF COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF ORAL TRAUMATIC DISEASES | |
| ATE553772T1 (en) | USE OF LVV HEMORPHIN-6 AND OPTIONAL AF12198 AS THERAPEUTIC AGENT(S). | |
| RU2008133287A (en) | PHARMACEUTICAL GEL-CONTAINING COMPOSITION FOR LOCAL AND OUTDOOR USE | |
| Huber et al. | The head and neck radiation oncology patient. | |
| AR044200A1 (en) | COMPOSITION OF FONDAPARINUX SODICO DE HIGH PURITY, A PROCEDURE FOR THE PREPARATION OF THIS COMPOSITION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT AS AN ACTIVE PRINCIPLE | |
| UA87123C2 (en) | Aqueous suspensions of ciclesonide for nebulisation | |
| DE60306546D1 (en) | INFLAMMATORY 3-ARYLTHIO-3-THIAZOLYL ALKYLAMINE | |
| KR20250143851A (en) | Novel multifunctional oligopeptides | |
| DE60019086D1 (en) | COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES | |
| RU2550957C1 (en) | Method of treating chronic generalised periodontitis | |
| NO20071238L (en) | Methods for healing damage by human IL-18 administration | |
| RU2008130566A (en) | MEANS FOR LOCAL TREATMENT OF PERIODONTAL DISEASES AND ORAL MUCOSURES | |
| RU2420257C1 (en) | Dental gel with chlorhexidine and dibunole for treatment of inflammatory diseases of parodentium and oral cavity mucosa | |
| RU2010153517A (en) | ANTI-MICROBIAL COMPOSITION | |
| WO2024260465A1 (en) | New multi-functional oligopeptides | |
| TW200640465A (en) | New pharmaceutically active compounds for the treatment of respiratory diseases | |
| RU2508101C1 (en) | Combined soft dosage form for local treatment of periodontics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130814 |